Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 20/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 11/20 | 0.45 |
| ▸ | PTPRC | P08575 | 2/20 | 0.45 |
| ▸ | PTPRA | P18433 | 2/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | PTPRE | P23469 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836756 | 1.00 | PTPN1 (0.45) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5841472 | 0.93 | KMT2A (0.38) | PTPN1PTPN2PTPRCPTPRA | |
| SCHEMBL5838054 | 0.90 | PTPN1 (0.40) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5837799 | 0.87 | PTPN1 (0.46) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5837530 | 0.86 | PTPN1 (0.44) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5837583 | 0.86 | PTPN1 (0.44) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5838274 | 0.85 | PTPN1 (0.45) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5837650 | 0.83 | PTPN1 (0.41) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL5838719 | 0.83 | PTPN1 (0.41) | PTPN1PTPN2PTPRCPTPRAPTPRB | |
| SCHEMBL7564276 | 0.81 | CYP1A2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | claimed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | claimed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | claimed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | claimed |
| EP-1214060-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | claimed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | claimed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | claimed |
| US-11192850-B2 | N-aryl oxamic acids | PURDUE RESEARCH FOUNDATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PURDUE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | US | disclosed |
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214060-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PTPRB, PTPRO, PTPRM | PTPN1 14/4885PTPN2 22/4885PTPRC 12/4885 |
| US-11192850-B2 | N-aryl oxamic acids | PTPRB, PTPRO, PTPRM | PTPN1 13/4885PTPN2 19/4885PTPRC 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.